Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luc Janssens

Showing results (81-90 of 114) with videos related to

Pageof 12
Sort By:
Journal of Alzheimer'S Disease : JAD|March 15, 2021
Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure HydrocephalusHeikki Lukkarinen, Ina Tesseur, Darrel Pemberton, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|August 15, 2019
Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trialNorihiro Kogame, Ply Chichareon, Kenneth De Wilder, et al.
JACC. Cardiovascular Interventions|February 23, 2010
Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events)Gilles Montalescot, Stephen G Ellis, Mark A de Belder, et al.
International Journal of Cardiology|August 10, 2025
Deferred revascularization of left main stenosis based on instantaneous wave-free ratio: Long-term clinical outcomes from the PHYNAL registryAlice Benedetti, Chiara Fusi, Mathieu Coeman, et al.
Lancet (London, England)|September 1, 2018
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trialPascal Vranckx, Marco Valgimigli, Peter Jüni, et al.
Journal of the American Heart Association|March 1, 2022
Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS TrialFelice Gragnano, Marcel Zwahlen, Pascal Vranckx, et al.
JACC. Cardiovascular Interventions|October 24, 2009
1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trialStephen G Ellis, Michal Tendera, Mark A de Belder, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|May 2, 2022
Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trialMasafumi Ono, Yoshinobu Onuma, Hideyuki Kawashima, et al.
Acta Cardiologica|August 7, 2020
The evolution of the CTO-PCI landscape in Belgium and Luxembourg: a four-year appraisalWard Eertmans, Peter Kayaert, Johan Bennett, et al.
Lancet (London, England)|September 8, 2018
Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trialAlexandra Lansky, William Wijns, Bo Xu, et al.
Pageof 12

Showing results (81-90 of 114) with videos related to

Sort By:
Pageof 12
Journal of Alzheimer'S Disease : JAD|March 15, 2021
Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure HydrocephalusHeikki Lukkarinen, Ina Tesseur, Darrel Pemberton, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|August 15, 2019
Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trialNorihiro Kogame, Ply Chichareon, Kenneth De Wilder, et al.
JACC. Cardiovascular Interventions|February 23, 2010
Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events)Gilles Montalescot, Stephen G Ellis, Mark A de Belder, et al.
International Journal of Cardiology|August 10, 2025
Deferred revascularization of left main stenosis based on instantaneous wave-free ratio: Long-term clinical outcomes from the PHYNAL registryAlice Benedetti, Chiara Fusi, Mathieu Coeman, et al.
Lancet (London, England)|September 1, 2018
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trialPascal Vranckx, Marco Valgimigli, Peter Jüni, et al.
Journal of the American Heart Association|March 1, 2022
Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS TrialFelice Gragnano, Marcel Zwahlen, Pascal Vranckx, et al.
JACC. Cardiovascular Interventions|October 24, 2009
1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trialStephen G Ellis, Michal Tendera, Mark A de Belder, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|May 2, 2022
Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trialMasafumi Ono, Yoshinobu Onuma, Hideyuki Kawashima, et al.
Acta Cardiologica|August 7, 2020
The evolution of the CTO-PCI landscape in Belgium and Luxembourg: a four-year appraisalWard Eertmans, Peter Kayaert, Johan Bennett, et al.
Lancet (London, England)|September 8, 2018
Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trialAlexandra Lansky, William Wijns, Bo Xu, et al.
Pageof 12